Skip to main content



Genentech WO42633
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (Her2-) Primary Breast Cancer
Minimal Clinically Important Difference in FACIT-Fatigue Scale in patients with locally advanced or metastatic breast cancer receiving treatment with taxane-based chemotherapy
A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants With Advanced Breast Cancer

Head and Neck



Loxo Oncology LOXO-BTK-20020
A Phase 3, Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUN CLL-321)
Loxo Oncology LOXO-BTK-20022
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)


Janssen NSC3003 MARIPOSA
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Mariposa)
Astra Zeneca D9106C00001 AEGEAN
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant / Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-Small Cell Lung Cancer (AEGEAN)
Mirati Therapeutics MRTX- 849-007 KRYSTAL-7
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
BMS CA224-104
A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Mirati Therapeutics MRTX 849-012 KRYSTAL-12
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation


AstraZeneca D8220R00004
Treatment Pattern, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents
Genentech MO40598
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GEMOX) Versus R-Gemox Alone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Epizyme EZH-302
A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituxumab in Subjects with Relapsed/Refractory Follicular Lymphoma
Incyte INCMOR 0208-301
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Tafasitamab plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3A or R/R Marginal Zone Lymphoma (MZL)


Multiple Myeloma

Janssen MMY3021
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Oncotherapeutics I-RUX-15-04
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Myelodysplastic Syndromes

Celgene Connect Myeloid
Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry


Novocure Panova-3
PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma


Janssen PCR0002 Prevalence
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer
67652000PCR3002 Amplitude
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Novartis CAAA617C12301
PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Solid Tumor

MCLA-128-CL01 Merus
A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
DOT Therapeutics Day 101-102A
A Phase 2, Subprotocol of Day101 Monotherapy for Patients with Recurrent, Progressive, or Refractory Solid Tumors with Activating BRAF Gene Fusion
AnHeart Therapeutics TRUST-II
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors

Supportive Care

Lutris Pharma L-02-01
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions


BMS CA209-901 CheckMate 901
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer **enrolling in Arms C & D (cisplatin-eligible patients)

Blood Draw

Exact Sciences 2018-01B
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01: "Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors"
Exact Sciences 2018-01
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors
Seer 020102
A Prospective Blood Sample Collection Study to Evaluate a Panel of Protein-based Biomarkers

Tempus Time Trial Program

CSNF is part of The TIME Trial Program, a just-in-time network of providers that supports rapid patient identification, site activation, and enrollment of select clinical trials. Building off of existing relationships with a large network of community hospitals and practices, TIME activates clinical trials at pre-qualified sites in its network in an average of 10 days, bringing the very best clinical trials to community centric parts of this country and giving access to thousands of patients that have historically been denied novel therapeutics. As part of The TIME Trial Network, CSNF has access to the biggest marketplace of trials that can be quickly initiated when there is a patient on-site that is ready to enroll. The program's just-in-time model allows for both sites and sponsors to locate extremely rare patients and then open a trial specifically on that patient’s behalf in a fraction of the time it typically takes.